HOME > Our Company > Our Business > Overseas Development

Overseas Development

We are taking up the global challenge through overseas expansion and corporate alliances.

Taisho is a world-class leading company in the field of OTC medicines, marketing a variety of products on a global scale. Taisho has made concerted efforts to promote its Lipovitan D nutrient drink overseas. Lipovitan began its journey overseas in 1963, and is now manufactured and sold by subsidiaries located in Hong Kong, Taiwan, Malaysia, the Philippines, Indonesia, Thailand, Vietnam, China, Australia, the United States and the United Kingdom. The Company is particularly strengthening sales promotion activities in the huge market of more than 1.2 billion people in China through bases in Shanghai, Beijing and Guangzhou. In 1998, Taisho began selling LIBOGEN (Lipovitan) in China. We also launched the nutrient drink Libaojian Yirenzhuang (Lipovitan Alfe), targeting women who are active socially in China, which is experiencing sharp economic growth. In 1991, we took our first steps in the European market, and Taisho Pharmaceutical (Europe) Ltd. was established in London in 1998 as a base for business expansion and to oversee our operations throughout the continent.

In the prescription drugs markets, Taisho sells a popular macrolide antibiotic agent Clarith through Abbott Laboratories of the United States in approximately 90 countries around the world. In collaboration with overseas companies and the introduction of new technologies, Taisho aims to be a global prescription pharmaceutical manufacturer that provides innovative products to people around the world.

Page Top